Drug Trial Radar · NCT07304089
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 5, 2026
Primary completion
Mar 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Vima TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia. The main objectives of this clinical trial are to determine the following: * Does VIM0423 therapy improve dystonia symptoms compared to placebo? * Is VIM0423 well tolerated in individuals with isolated dystonia? and * Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?
Conditions
- Dystonia
Interventions
VIM0423Drug
VIM0423 is a combination drug product containing two active ingredients (VMA-1001 and VMA-1002)
VIM0423 PlaceboDrug
Matching VIM0423 placebo product containing no active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Burke-Fahn-Marsden (BFM) Dystonia Rating ScaleTime frame: From baseline to Week 14
Locations
45 sites in 2 countries. Site status is shown where the registry gives one.
Vima Site #033
Birmingham, Alabama · Recruiting
Vima Site #039
Scottsdale, Arizona · Recruiting
Vima Site #004
Scottsdale, Arizona · Recruiting
Vima Site #028
Sun City, Arizona · Recruiting
Vima Site #042
Irvine, California · Recruiting
Vima Site #030
Los Angeles, California · Recruiting
Vima Site #061
Sacramento, California · Not yet recruiting
Vima Site #056
Aurora, Colorado · Not yet recruiting
Vima Site #019
Denver, Colorado · Recruiting
Vima Site #069
Vernon, Connecticut · Not yet recruiting
Vima Site #009
Gainesville, Florida · Recruiting
Vima Site #008
Miami, Florida · Recruiting
Vima Site #031
Orlando, Florida · Recruiting
Vima Site #005
Atlanta, Georgia · Recruiting
Vima Site #027
Chicago, Illinois · Recruiting
Vima Site #041
Overland Park, Kansas · Recruiting
Vima Site #043
Baltimore, Maryland · Recruiting
Vima Site #007
Olney, Maryland · Recruiting
Vima Site #032
Boston, Massachusetts · Recruiting
Vima Site #037
East Lansing, Michigan · Recruiting
Vima Site #002
Farmington Hills, Michigan · Recruiting
Vima Site #038
St Louis, Missouri · Recruiting
Vima Site #014
Albuquerque, New Mexico · Recruiting
Vima Site #055
Amherst, New York · Not yet recruiting
Vima Site #018
New York, New York · Recruiting
Vima Site #024
New York, New York · Recruiting
Vima Site #036
Rochester, New York · Recruiting
Vima Site #040
Fayetteville, North Carolina · Recruiting
Vima Site #035
Cincinnati, Ohio · Recruiting
Vima Site #029
Portland, Oregon · Recruiting
Vima Site #020
Philadelphia, Pennsylvania · Recruiting
Vima Site #021
Charleston, South Carolina · Recruiting
Vima Site #016
Memphis, Tennessee · Recruiting
Vima Site #006
Nashville, Tennessee · Recruiting
Vima Site #025
Dallas, Texas · Recruiting
Vima Site #026
Georgetown, Texas · Recruiting
Vima Site #012
Houston, Texas · Recruiting
Vima Site #013
Houston, Texas · Recruiting
Vima Site #011
Richmond, Virginia · Recruiting
Vima Site #023
Kirkland, Washington · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.